SELLAS Life Sciences (SLS) Cash & Equivalents (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Cash & Equivalents for 9 consecutive years, with $100000.0 as the latest value for Q3 2024.
- Quarterly Cash & Equivalents fell 97.5% to $100000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Sep 2024, down 97.5% year-over-year, with the annual reading at $2.5 million for FY2023, 85.23% down from the prior year.
- Cash & Equivalents for Q3 2024 was $100000.0 at SELLAS Life Sciences, roughly flat from $100000.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $35.3 million in Q4 2020, with the low at $100000.0 in Q1 2020.
- Average Cash & Equivalents over 5 years is $7.4 million, with a median of $100000.0 recorded in 2020.
- The sharpest move saw Cash & Equivalents surged 35202.0% in 2020, then plummeted 99.64% in 2022.
- Over 5 years, Cash & Equivalents stood at $35.3 million in 2020, then tumbled by 39.51% to $21.4 million in 2021, then dropped by 19.81% to $17.1 million in 2022, then crashed by 85.23% to $2.5 million in 2023, then tumbled by 96.05% to $100000.0 in 2024.
- According to Business Quant data, Cash & Equivalents over the past three periods came in at $100000.0, $100000.0, and $100000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.